TFA Therapeutics (RAJAF) Non-Current Debt (2020 - 2023)

TFA Therapeutics has reported Non-Current Debt for 4 years, with the latest figure at $431079.0 in Q4 2023.

• On a quarterly basis, Non-Current Debt rose 4.13% year-over-year to $431079.0 in Q4 2023; TTM through Dec 2023 was $431079.0, a 4.13% increase from a year earlier, with the FY2023 full-year figure at $431079.0, up 4.13% from the prior year.
• Non-Current Debt was $431079.0 for Q4 2023 at TFA Therapeutics, up from $414000.0 in the prior quarter.
• The five-year high for Non-Current Debt was $431079.0 in Q4 2023, with the low at $414000.0 in Q4 2020.
• Average Non-Current Debt over 4 years is $417415.8, with a median of $414000.0 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Non-Current Debt changed 0.0% in 2021, then climbed 4.13% in 2023.
• Over 4 years, Non-Current Debt stood at $414000.0 in 2020, then changed by 0.0% to $414000.0 in 2021, then changed by 0.0% to $414000.0 in 2022, then climbed by 4.13% to $431079.0 in 2023.
• The last three Non-Current Debt figures came in at $431079.0 (Q4 2023), $414000.0 (Q3 2023), and $414000.0 (Q4 2022), per Business Quant data.